pTVG-HP
Phase 2Biologic
pTVG-HP is one of 49 biologic programs targeting Prostate Cancer. It is currently in Phase 2.
3
Indications
7
Total Trials
3
Active Trials
48
Competitors
Pipeline
Status by Indication[3][1]
Indication
Competition
Competitive Landscape
314 competitors in Prostate Cancer
#DrugCompanyPhaseTrials
1Opdivo
Bristol-Myers SquibbPhase 3
Lupron
EEastern Cooperative Oncology Group
Phase 3
Nizoral
WWim Janssens
Phase 3
Tecentriq
RochePhase 3
Lipitor
PPfizer's Upjohn has merged with Mylan to form Viatris Inc.
Phase 3
GM-CSF
YY-mAbs Therapeutics
Phase 3
pTVG-HP
UUniversity of Wisconsin, Madison
Phase 2
Trexall
Jazz PharmaceuticalsPreclinical
Jatenzo
GGrupo Espanol de Tumores Neuroendocrinos
Preclinical
Botox
VVitae Pharmaceuticals Inc., an Allergan affiliate
Preclinical
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Timeline
Expected Milestones
Clinical
Trials by Indication[1]
Prostate Cancer3 trials
Metastatic Prostate Cancer2 trials
Recurrent1 trial
Sources
References
- [1]
- [2]
- [3]Open Targets Platform — Drug–disease associations for pTVG-HP. EMBL-EBI & Wellcome Sanger Institute.
- [4]
Details
Drug Info
Quick Facts
- Modality
- Biologic[2]
- Highest Phase
- Phase 2[1]
- Company
- UUniversity of Wisconsin, Madison